News & Events

Press releases

Pneumagen Announces Appointment of John Beadle as Non-Executive Director

READ MORE...

Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022

READ MORE...

Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)

READ MORE...

Pneumagen initiates Phase 1 trial of Neumifil, a novel, intranasal pan anti-viral therapeutic for the prophylaxis and treatment of viral Respiratory Tract Infections

READ MORE...

Pneumagen Appoints New Head of Research to Expand its Anti-Viral Pipeline leveraging its Proprietary GlycoTarge™ Platform

READ MORE...

Pneumagen Announces Neumifil™ is Efficacious In an Established Model of COVID-19 Infection

READ MORE...

Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year

READ MORE...

Pneumagen’s Neumifil for combating COVID-19 featured in SCRIP’s 10 to watch at BIO-Europe Digital

READ MORE...

Pneumagen Announces Scientific Advisory Board and Development Team Appointments

READ MORE...

Event information

Jefferies London Healthcare Conference | November 15th – 17th 2022

READ MORE...

BIO-Europe in Leipzig | October 24th – 26th 2022

READ MORE...

BIO International Convention in San Diego | June 13th – 16th 2022

READ MORE...

Bio€quity Europe in Milan | May 16th – 18th 2022

READ MORE...

BioTrinity 2022 in London | April 26th – 27th 2022

READ MORE...

BIO-Europe Spring Digital | March 28th – 30th 2022

READ MORE...